| Active substance | acalabrutinib |
| Holder | AstraZeneca n.v./s.a. |
| Status | Running |
| Indication | treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 25/07/2025 |